Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit

Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508  
New translational analyses combining group 1 & group 2 continue to support...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Oregon ,University Of Pennsylvania ,Michael Klichinsky ,Kima Reiss ,Exchange Commission ,Prnewswire Carisma Therapeutics Inc ,Oregon Health Science University ,Carisma Therapeutics Inc ,Penn Medicine Abramson Cancer Center ,Perelman School Of Medicine ,Md Anderson Cancer Center ,Nasdaq ,Company Quarterly Report On Form ,Exchange Commission On ,Penn Perelman School Of Medicine ,Fred Hutchinson Cancer Center ,City Of Hope National Medical Center ,Sarah Cannon Cancer Research Institute ,Perelman School ,Chief Scientific Officer ,Current Report ,Penn Medicine ,Abramson Cancer Center ,Hope National Medical Center ,Cancer Center ,Oregon Health ,Science University ,Fred Hutchinson Cancer ,Private Securities Litigation Reform Act ,Quarterly Report ,Markets ,